Drug Approval | March 07, 2025
Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
VITADEETM Green is a 100% plant-based Vitamin D3 suitable for food & nutraceuticals
ANVIMO will be available in dosages of 240 mg and 480 mg
Melicica has potential applications in skin repair, scar and acne-prone skin care, tone evening and brightening, texture improvement, baby care, sensitive skin solutions, post-procedure recovery and stretch mark care
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
